Cwm LLC Sells 199 Shares of Revvity Inc. (NYSE:RVTY)

Cwm LLC reduced its position in shares of Revvity Inc. (NYSE:RVTY) by 7.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,642 shares of the company’s stock after selling 199 shares during the period. Cwm LLC’s holdings in Revvity were worth $279,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its position in Revvity by 16.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company’s stock worth $2,317,170,000 after purchasing an additional 2,969,326 shares during the last quarter. EdgePoint Investment Group Inc. grew its position in shares of Revvity by 51.1% in the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company’s stock valued at $452,939,000 after buying an additional 1,372,456 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Revvity by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company’s stock valued at $851,764,000 after buying an additional 1,151,821 shares during the period. Norges Bank bought a new position in shares of Revvity during the fourth quarter worth about $127,801,000. Finally, GAMMA Investing LLC raised its position in shares of Revvity by 15,023.0% during the first quarter. GAMMA Investing LLC now owns 287,035 shares of the company’s stock worth $30,368,000 after acquiring an additional 285,137 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Price Performance

Shares of NYSE RVTY opened at $103.73 on Friday. The firm has a market capitalization of $12.23 billion, a P/E ratio of 44.14, a P/E/G ratio of 2.61 and a beta of 0.98. The firm’s 50-day moving average price is $95.53 and its 200-day moving average price is $103.35. The company has a current ratio of 3.58, a quick ratio of 2.99 and a debt-to-equity ratio of 0.41. Revvity Inc. has a 1-year low of $87.70 and a 1-year high of $129.50.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The business had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. During the same period in the previous year, the company posted $0.98 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Friday, October 17th. Revvity’s payout ratio is 11.91%.

Analysts Set New Price Targets

RVTY has been the topic of several analyst reports. Wells Fargo & Company reduced their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Evercore ISI reduced their price objective on shares of Revvity from $116.00 to $115.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. UBS Group upgraded shares of Revvity from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Raymond James Financial restated an “outperform” rating and issued a $120.00 target price (down previously from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Finally, Bank of America cut their price target on shares of Revvity from $116.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Revvity has an average rating of “Moderate Buy” and a consensus target price of $123.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.